Lantheus announces MK-6250 study met co-primary endpoints

Lantheus (LNTH) announced that its clinical-stage F18-labeled tau Positron Emission Tomography, PET, radiodiagnostic, MK-6240, successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. This achievement reinforces the potential of MK-6240 as a valuable diagnostic tool. The data from these two studies will support a New Drug Application, NDA, submission to the U.S. Food and Drug Administration, FDA, expected to be filed in the third quarter of 2025. “The clinical results of MK-6240 underscore our commitment to providing cutting-edge imaging solutions for Alzheimer’s disease that align with the latest scientific advancements,” said Brian Markison, CEO, Lantheus. “With MK-6240 successfully meeting its primary endpoints in both pivotal studies, we are moving closer to delivering this innovative radiodiagnostic to potentially support precise diagnoses and improve disease management.”